A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma

Alcon

Status and phase: Completed; Phase 3

Conditions: Ocular Hypertension; Glaucoma, Angle-Closure

Treatments: Drug: Latanoprost (0.005%); Drug: Travoprost (0.004%)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00051181

C-01-38

Details and patient eligibility

About

To demonstrate that the intraocular pressure(IOP)-lowering efficacy of Travoprost (0.004%) is equal or better than that of Latanoprost 0.005% in patients with chronic angle-closure glaucoma.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Adult patients of any race and either sex with chronic angle-closure glaucoma.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind